Back to top
more

AMN Healthcare Services (AMN)

(Real Time Quote from BATS)

$16.72 USD

16.72
1,014,022

-0.20 (-1.18%)

Updated Aug 8, 2025 01:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (97 out of 244)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Thermo Fisher (TMO) Debuts GMP-Manufactured Cas9 Protein

by Zacks Equity Research

Thermo Fisher's (TMO) Gibco CTS TrueCut Cas9 Protein to support genome editing for research and manufacturing applications.

Zacks Equity Research

Here's Why You Should Hold on to CONMED (CNMD) Stock Now

by Zacks Equity Research

CONMED (CNMD) continues to gain momentum from a solid product portfolio and strong General Surgery business. However, data security threats linger.

Zacks Equity Research

McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Zacks Equity Research

Catalent's (CTLT) Latest Manufacturing Suites to Boost Capacity

by Zacks Equity Research

Catalent's (CTLT) latest site expansion is expected to significantly boost its business.

Zacks Equity Research

Henry Schein (HSIC) Stock Moves Up 20.6%: What's Driving It?

by Zacks Equity Research

Henry Schein's (HSIC) stock rallied on strong fourth-quarter performance and bullish 2022 EPS guidance.

Zacks Equity Research

Here's Why You Should Hold on to Insulet (PODD) Stock For Now

by Zacks Equity Research

Investors are optimistic about Insulet (PODD) on robust uptake of the Omnipod system and bullish guidance.

Zacks Equity Research

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.

Zacks Equity Research

AMN Healthcare Services (AMN) Stock Moves -1.11%: What You Should Know

by Zacks Equity Research

AMN Healthcare Services (AMN) closed the most recent trading day at $104, moving -1.11% from the previous trading session.

Zacks Equity Research

DexCom (DXCM) G6 CGM System Now Available to TRICARE Members

by Zacks Equity Research

The availability of DexCom's (DXCM) G6 CGM System to diabetic TRICARE military members is expected to enable them to make better real-time decisions about their health.

Zacks Equity Research

Fresenius Medical (FMS) Launches Campaign to Boost Kidney Care

by Zacks Equity Research

Fresenius Medical's (FMS) My Reason campaign will help scientists understand genetic variations in patients with chronic kidney disease in a better way.

Zacks Equity Research

Here's Why You Should Retain Phibro (PAHC) Stock For Now

by Zacks Equity Research

Investors are optimistic about Phibro (PAHC) owing to the robust performances by its Animal Health and Mineral Health segments.

Zacks Equity Research

Integer Holdings' (ITGR) Latest Buyout to Expand Its Footprint

by Zacks Equity Research

Integer Holdings' (ITGR) buyout of Aran Biomedical is set to expand its presence in high-growth markets as well as enhance its product offerings.

Zacks Equity Research

Masimo's (MASI) Sound United Buyout to Boost Product Portfolio

by Zacks Equity Research

Masimo's (MASI) completion of Sound United's buyout to help enhance the former's extended portfolio of hospital and home medical technology solutions.

Zacks Equity Research

Illumina (ILMN) Launches Genomic Solution Hub in Brazil

by Zacks Equity Research

Illumina's (ILMN) customers and partners in Brazil currently span basic research, applied markets to clinical labs and healthcare institutions.

Zacks Equity Research

Here's Why You Should Retain SmileDirectClub (SDC) For Now

by Zacks Equity Research

Investors are optimistic about SmileDirectClub's (SDC) series of cutting-edge innovation, strategic distribution and insurance partnerships.

Zacks Equity Research

Bruker (BRKR) Unveils New Imaging Tools for Cancer Research

by Zacks Equity Research

Bruker's (BRKR) latest innovation for cancer research is likely to strengthen the company's opportunities in proteomics and spatial biology.

Zacks Equity Research

Merit Medical's (MMSI) SCOUT Bx Delivery System Gets FDA Nod

by Zacks Equity Research

Merit Medical's (MMSI) receipt of FDA clearance for the SCOUT Bx system can streamline treatment for cancer patients.

Zacks Equity Research

Alcon (ALC) Stock Rallies 4.7% Since Posting Q4 Earnings Beat

by Zacks Equity Research

Alcon (ALC) stock rallies on robust growth across all Surgical and Vision Care sales categories.

Zacks Equity Research

Quidel Corporation (QDEL) Reports Solid Preliminary Q1 Revenues

by Zacks Equity Research

Quidel's (QDEL) revenue growth in the first quarter is likely to have been boosted by continued robust sales of its SARS-related products.

Zacks Equity Research

Abiomed (ABMD) Announces Successful Usage of Impella in Japan

by Zacks Equity Research

Continued adoption of Abiomed's (ABMD) Impella 5.5 with SmartAssist is likely to provide a minimally invasive surgical option for acute heart failure patients.

Zacks Equity Research

Here's Why You Should Hold on to Walgreens Boots (WBA) For Now

by Zacks Equity Research

Investors are optimistic about Walgreens (WBA) owing to the recent product launches.

Zacks Equity Research

Cardinal Health (CAH) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.

Zacks Equity Research

AmerisourceBergen's (ABC) Venture Capital Fund to Aid Healthcare

by Zacks Equity Research

AmerisourceBergen's (ABC) new corporate venture capital fund to help emerging healthcare startup companies change healthcare for people and animals globally.

Zacks Equity Research

Here's Why You Should Retain West Pharmaceutical (WST) Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

Zacks Equity Research

Henry Schein (HSIC) Hits a New 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC) owing to favorable dental business trends and a strong solvency position.